Skip to main content

Advertisement

Table 1 Baseline characteristics in patients with ankylosing spondylitis by subgroup of enthesitis or peripheral arthritis or both

From: Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis

  Patient subgroups
Characteristic No enthesitis
+ no arthritis (n = 457)
Enthesitis
+ no arthritis (n = 512)
Arthritis
+ no enthesitis (n = 107)
Enthesitis
+ arthritis
(n = 174)
Age, years 43.1 ± 11.2 42.7 ± 11.1 46.0 ± 11.9 46.1 ± 12.3
Males, percentage 80.7 67.8 69.2 58.0
HLA-B27-positive, percentage 83.7 82.2 84.1 76.0
AS duration, years 10.9 ± 9.4 10.5 ± 9.7 12.3 ± 10.6 11.8 ± 10.5
Advanced AS, percentage 25.2 28.4 27.6 26.5
Concomitant NSAIDs, percentage 74.0 76.8 73.8 68.4
Concomitant DMARDs, percentage 21.7 22.1 45.8 35.6
Concomitant glucocorticoidsa, percentage 10.1 10.9 29.9 20.1
Prior TNF-antagonist therapy, percentage 25.8 25.0 27.1 29.3
  1. Data are mean ± standard deviation unless otherwise noted. aSystemic treatment with not more than 10 mg of prednisone equivalent daily. AS, ankylosing spondylitis; DMARD, disease-modifying antirheumatic drug; NSAID, nonsteroidal anti-inflammatory drug; TNF, tumor necrosis factor.